Biological and medical applications of a brain-on-a-chip

Experimental Biology and Medicine

Volumn 239, Issue 9, 2014, Pages 1096-1107

  Pamies, David ^a,b   Hartung, Thomas ^a,b   Hogberg, Helena T ^a,b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF KONSTANZ   (Germany)

Author keywords

human on a chip; Induced pluripotent stem cells; neural models; three dimensional; Tox 21 c

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; BRAIN BLOOD VESSEL; BRAIN ON CHIP; DISEASE MODEL; DRUG EFFICACY; DRUG RESEARCH; GENE EXPRESSION; HUMAN; MICROPHYSIOLOGICAL SYSTEM; NERVE CELL CULTURE; NERVE CELL DIFFERENTIATION; NEURAL STEM CELL; NEUROLOGICAL THERAPEUTIC DEVICE; NONHUMAN; PLURIPOTENT STEM CELL; ANIMAL; BRAIN; DRUG SCREENING; EQUIPMENT; HUMAN-ON-A-CHIP; LAB ON A CHIP; METHODOLOGY; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NEURAL MODELS; ORGAN CULTURE TECHNIQUE; RAT; REVIEW; THREE-DIMENSIONAL; TOX-21 C;

HUMAN-ON-A-CHIP; INDUCED PLURIPOTENT STEM CELLS; NEURAL MODELS; THREE-DIMENSIONAL; TOX-21 C;

ANIMALS; BRAIN; DRUG EVALUATION, PRECLINICAL; HUMANS; LAB-ON-A-CHIP DEVICES; NEUROGENESIS; NEURONAL PLASTICITY; ORGAN CULTURE TECHNIQUES; RATS;

EID: 84907010370     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/1535370214537738     Document Type: Article

References (146)

1. FDA. Federal Register. FDA 2002, http://www.gpo.gov/fdsys/pkg/FR-2002-05-31/pdf/02-13583.pdf (accessed 15 October 2013).
2. Gronvall GK,Trent D,Borio L,Brey R,Nagao L.The FDA animal efficacy rule and biodefense.Nat Biotechnol. 2007;25:1084-7
3. Hartung T.Toxicology for the twenty-first century.Nature. 2009;460:208-12
4. Hartung T.Food for thought….on animal tests. Altex. 2008;25:3-16
5. Hartung T.Look back in anger – what clinical studies tell us about preclinical work.Altex. 2013;30:275-91
6. Hartung T.Food for thought….on cell culture. Altex. 2007;24:143-52
7. Hartung T,Hoffmann S.Food for thought ….on in silico methods in toxicology. Altex. 2009;26:155-66
8. National research council: committee on animal models for assessing countermeasures to bioterrorism agents. Washington, DC: The National Academies Press; 2011:
9. Toxicity testing in the 21st century: a vision and a strategy. Washington, DC: The National Academies Press; 2007:
10. Hartung T,Zurlo J.Alternative approaches for medical countermeasures to biological and chemical terrorism and warfare.Altex. 2012;29:251-60
11. Boyle CA,Decoufle P,Yeargin-Allsopp M.Prevalence and health impact of developmental disabilities in US children.Pediatrics. 1994;93:399-403
12. Grandjean P,Landrigan PJ.Developmental neurotoxicity of industrial chemicals.Lancet. 2006;368:2167-78
13. Schettler T.Toxic threats to neurologic development of children.Environmental health perspectives. 2001;109:813-6
14. Ema M,Fukui Y,Aoyama H,Fujiwara M,Fuji J,Inouye M,Iwase T,Kihara T,Oi A,Otani H,Shinomiya M,Sugioka K,Yamano T,Yamashita KH,Tanimura T.Comments from the developmental neurotoxicology committee of the Japanese teratology society on the OECD guideline for the testing of chemicals, proposal for a new guideline 426, developmental neurotoxicity study, draft document (October 2006 version), and on the draft document of the retrospective performance assessment of the draft test guideline 426 on developmental neurotoxicity.Congenit Anom (Kyoto). 2007;47:74-6
15. Kuehn BM.Increased risk of ADHD associated with early exposure to pesticides, PCBs.JAMA. 2010;304:27-8
16. Sagiv SK,Thurston SW,Bellinger DC,Tolbert PE,Altshul LM,Korrick SA.Prenatal organochlorine exposure and behaviors associated with attention deficit hyperactivity disorder in school-aged children.Am J Epidemiol. 2010;171:593-601
17. Rodier PM.Vulnerable periods and processes during central nervous system development.Environ Health Perspect. 1994;102:121-4
18. Aschner M,Allen JW,Kimelberg HK,LoPachin RM,Streit WJ.Glial cells in neurotoxicity development.Ann Rev Pharmacol Toxicol. 1999;39:151-73
19. Baumann N,Pham-Dinh D.Biology of oligodendrocyte and myelin in the mammalian central nervous system.Physiol Rev. 2001;81:871-927
20. Parpura V,Basarsky TA,Liu F,Jeftinija K,Jeftinija S,Haydon PG.Glutamate-mediated astrocyte-neuron signalling.Nature. 1994;369:744-7
21. Kinsner A,Pilotto V,Deininger S,Brown GC,Coecke S,Hartung T,Bal-Price A.Inflammatory neurodegeneration induced by lipoteichoic acid from Staphylococcus aureus is mediated by glia activation, nitrosative and oxidative stress, and caspase activation.J Neurochem. 2005;95:1132-43
22. Bal-Price AK,Hogberg HT,Buzanska L,Coecke S.Relevance of in vitro neurotoxicity testing for regulatory requirements: challenges to be considered.Neurotoxicol Teratol. 2010;32:36-41
23. Dityatev A,Schachner M.Extracellular matrix molecules and synaptic plasticity.Nat Rev Neurosci. 2003;4:456-68
24. Yamaguchi Y.Lecticans: organizers of the brain extracellular matrix.Cell Mol Life Sci: CMLS. 2000;57:276-89
25. Bandtlow CE,Zimmermann DR.Proteoglycans in the developing brain: new conceptual insights for old proteins.Physiol Rev. 2000;80:1267-90
26. Yayon A,Klagsbrun M,Esko JD,Leder P,Ornitz DM.Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor.Cell. 1991;64:841-8
27. Rauvala H,Peng HB.HB-GAM (heparin-binding growth-associated molecule) and heparin-type glycans in the development and plasticity of neuron-target contacts.Prog Neurobiol. 1997;52:127-44
28. Hartley RS,Margulis M,Fishman PS,Lee VM,Tang CM.Functional synapses are formed between human NTera2 (NT2N, hNT) neurons grown on astrocytes.J Comp Neurol. 1999;407:1-10
29. Liu Q,Spusta SC,Mi R,Lassiter RN,Stark MR,Hoke A,Rao MS,Zeng X.Human neural crest stem cells derived from human ESCs and induced pluripotent stem cells: induction, maintenance, and differentiation into functional schwann cells.Stem Cells Transl Med. 2012;1:266-78
30. Limongi T,Cesca F,Gentile F,Marotta R,Ruffilli R,Barberis A,Dal Maschio M,Petrini EM,Santoriello S,Benfenati F,Di Fabrizio E.Nanostructured superhydrophobic substrates trigger the development of 3D neuronal networks.Small. 2013;9:402-12
31. Peretz H,Talpalar AE,Vago R,Baranes D.Superior survival and durability of neurons and astrocytes on 3-dimensional aragonite biomatrices.Tissue Eng. 2007;13:461-72
32. Brannvall K,Bergman K,Wallenquist U,Svahn S,Bowden T,Hilborn J,Forsberg-Nilsson K.Enhanced neuronal differentiation in a three-dimensional collagen-hyaluronan matrix.J Neurosci Res. 2007;85:2138-46
33. Serra M,Brito C,Costa EM,Sousa MF,Alves PM.Integrating human stem cell expansion and neuronal differentiation in bioreactors.BMC Biotechnol. 2009;9:82-82
34. Jurga M,Lipkowski AW,Lukomska B,Buzanska L,Kurzepa K,Sobanski T,Habich A,Coecke S,Gajkowska B,Domanska-Janik K.Generation of functional neural artificial tissue from human umbilical cord blood stem cells.Tissue Eng Part C Methods. 2009;15:365-72
35. Hogberg HT,Sobanski T,Novellino A,Whelan M,Weiss DG,Bal-Price AK.Application of micro-electrode arrays (MEAs) as an emerging technology for developmental neurotoxicity: evaluation of domoic acid-induced effects in primary cultures of rat cortical neurons.Neurotoxicology. 2011;32:158-68
36. Keefer EW,Gramowski A,Gross GW.NMDA receptor-dependent periodic oscillations in cultured spinal cord networks.J Neurophysiol. 2001;86:3030-42
37. Yla-Outinen L,Heikkila J,Skottman H,Suuronen R,Aanismaa R,Narkilahti S.Human cell-based micro electrode array platform for studying neurotoxicity.Front Neuroeng. 2010;3:1-9
38. Van Vliet E,Stoppini L,Balestrino M,Eskes C,Griesinger C,Sobanski T,Whelan M,Hartung T,Coecke S.Electrophysiological recording of re-aggregating brain cell cultures on multi-electrode arrays to detect acute neurotoxic effects.Neurotoxicology. 2007;28:1136-46
39. O’Shaughnessy TJ,Lin HJ,Ma W.Functional synapse formation among rat cortical neurons grown on three-dimensional collagen gels.Neurosci Lett. 2003;340:169-72
40. Pottler M,Zierler S,Kerschbaum HH.An artificial three-dimensional matrix promotes ramification in the microglial cell-line, BV-2.Neurosc Lett. 2006;410:137-40
41. Abbott A.Cell culture: biology’s new dimension.Nature. 2003;424:870-2
42. Cukierman E,Pankov R,Stevens DR,Yamada KM.Taking cell-matrix adhesions to the third dimension.Science. 2001;294:1708-12
43. Gassmann K,Baumann J,Giersiefer S,Schuwald J,Schreiber T,Merk HF,Fritsche E.Automated neurosphere sorting and plating by the COPAS large particle sorter is a suitable method for high-throughput 3D in vitro applications.Toxicol In Vitro. 2012;26:993-1000
44. Van Vliet E,Morath S,Eskes C,Linge J,Rappsilber J,Honegger P,Hartung T,Coecke S.A novel in vitro metabolomics approach for neurotoxicity testing, proof of principle for methyl mercury chloride and caffeine.Neurotoxicology. 2008;29:1-12
45. Forsby A,Bal-Price AK,Camins A,Coecke S,Fabre N,Gustafsson H,Honegger P,Kinsner-Ovaskainen A,Pallas M,Rimbau V,Rodriguez-Farre E,Sunol C,Vericat JA,Zurich MG.Neuronal in vitro models for the estimation of acute systemic toxicity.Toxicol In Vitro. 2009;23:1564-9
46. Coecke S,Goldberg AM,Allen S,Buzanska L,Calamandrei G,Crofton K,Hareng L,Hartung T,Knaut H,Honegger P,Jacobs M,Lein P,Li A,Mundy W,Owen D,Schneider S,Silbergeld E,Reum T,Trnovec T,Monnet-Tschudi F,Bal-Price A.Workgroup report: incorporating in vitro alternative methods for developmental neurotoxicity into international hazard and risk assessment strategies.Environ Health Perspect. 2007;115:924-31
47. Lein P,Locke P,Goldberg A.Meeting report: alternatives for developmental neurotoxicity testing.Environ Health Perspect. 2007;115:764-8
48. Lein P,Silbergeld E,Locke P,Goldberg AM.In vitro and other alternative approaches to developmental neurotoxicity testing (DNT).Environ Toxicol Pharmacol. 2005;19:735-44
49. Eskes C,Juillerat-Jeanneret L,Leuba G,Honegger P,Monnet-Tschudi F.Involvement of microglia-neuron interactions in the tumor necrosis factor-alpha release, microglial activation, and neurodegeneration induced by trimethyltin.J Neurosci Res. 2003;71:583-90
50. Zurich MG,Honegger P.Ochratoxin A at nanomolar concentration perturbs the homeostasis of neural stem cells in highly differentiated but not in immature three-dimensional brain cell cultures.Toxicol Lett. 2011;205:203-8
51. Zurich MG,Honegger P,Schilter B,Costa LG,Monnet-Tschudi F.Involvement of glial cells in the neurotoxicity of parathion and chlorpyrifos.Toxicol Appl Pharmacol. 2004;201:97-104
52. Hogberg HT,Kinsner-Ovaskainen A,Coecke S,Hartung T,Bal-Price AK.mRNA expression is a relevant tool to identify developmental neurotoxicants using an in vitro approach.Toxicol Sci. 2010;113:95-115
53. Hogberg HT,Kinsner-Ovaskainen A,Hartung T,Coecke S,Bal-Price AK.Gene expression as a sensitive endpoint to evaluate cell differentiation and maturation of the developing central nervous system in primary cultures of rat cerebellar granule cells (CGCs) exposed to pesticides.Toxicol Appl Pharmacol. 2009;235:268-86
54. Hogberg HT,Bressler J,Christian KM,Harris G,Makri G,O’Driscoll C,Pamies D,Smirnova L,Wen Z,Hartung T.Toward a 3D model of human brain development for studying gene/environment interactions.Stem Cell Res Ther. 2013;4:S4-S4
55. Labour MN,Banc A,Tourrette A,Cunin F,Verdier JM,Devoisselle JM,Marcilhac A,Belamie E.Thick collagen-based 3D matrices including growth factors to induce neurite outgrowth.Acta Biomaterialia. 2012;8:3302-12
56. Honegger P,Lenoir D,Favrod P.Growth and differentiation of aggregating fetal brain cells in a serum-free defined medium.Nature. 1979;282:305-8
57. Fritsche E,Gassmann K,Schreiber T.Neurospheres as a model for developmental neurotoxicity testing.Methods Mol Biol. 2011;758:99-114
58. Giobbe GG,Zagallo M,Riello M,Serena E,Masi G,Barzon L,Di Camillo B,Elvassore N.Confined 3D microenvironment regulates early differentiation in human pluripotent stem cells.Biotechnol Bioeng. 2012;109:3119-32
59. Abbott NJ.Evidence for bulk flow of brain interstitial fluid: significance for physiology and pathology.Neurochem Int. 2004;45:545-52
60. Schlageter KE,Molnar P,Lapin GD,Groothuis DR.Microvessel organization and structure in experimental brain tumors: microvessel populations with distinctive structural and functional properties.Microvasc Res. 1999;58:312-28
61. Wolburg H,Lippoldt A.Tight junctions of the blood-brain barrier: development, composition and regulation.Vasc Pharmacol. 2002;38:323-37
62. Krizanac-Bengez L,Mayberg MR,Janigro D.The cerebral vasculature as a therapeutic target for neurological disorders and the role of shear stress in vascular homeostatis and pathophysiology.Neurol Res. 2004;26:846-53
63. Abbott NJ.Astrocyte-endothelial interactions and blood-brain barrier permeability.J Anat. 2002;200:629-38
64. Abbott NJ,Patabendige AA,Dolman DE,Yusof SR,Begley DJ.Structure and function of the blood-brain barrier.Neurobiol Dis. 2010;37:13-25
65. Ando J,Yamamoto K.Vascular mechanobiology: endothelial cell responses to fluid shear stress.Circ J. 2009;73:1983-92
66. Prieto P,Blaauboer BJ,De Boer AG,Boveri M,Cecchelli R,Clemedson C,Coecke S,Forsby A,Galla HJ,Garberg P,Greenwood J,Price A,Tähti H.Blood-brain barrier in vitro models and their application in toxicology. The report and recommendations of ECVAM Workshop 49.Altern Lab Anim. 2004;32:37-50
67. Eigenmann DE,Xue G,Kim KS,Moses AV,Hamburger M,Oufir M.Comparative study of four immortalized human brain capillary endothelial cell lines, hCMEC/D3, hBMEC, TY10, and BB19, and optimization of culture conditions, for an in vitro blood-brain barrier model for drug permeability studies.Fluids Barriers CNS. 2013;10:33-33
68. Daneman R,Zhou L,Kebede AA,Barres BA.Pericytes are required for blood-brain barrier integrity during embryogenesis.Nature. 2010;468:562-6
69. Haseloff RF,Blasig IE,Bauer HC,Bauer H.In search of the astrocytic factor(s) modulating blood-brain barrier functions in brain capillary endothelial cells in vitro.Cell Mol Neurobiol. 2005;25:25-39
70. Achyuta AK,Conway AJ,Crouse RB,Bannister EC,Lee RN,Katnik CP,Behensky AA,Cuevas J,Sundaram SS.A modular approach to create a neurovascular unit-on-a-chip.Lab Chip. 2013;13:542-53
71. Bohara M,Kambe Y,Nagayama T,Tokimura H,Arita K,Miyata A.C-type natriuretic peptide modulates permeability of the blood-brain barrier.J Cereb Blood Flow Metab. 2014;34:589-96
72. Ponio JB,El-Ayoubi F,Glacial F,Ganeshamoorthy K,Driancourt C,Godet M,Perriere N,Guillevic O,Couraud PO,Uzan G.Instruction of circulating endothelial progenitors in vitro towards specialized blood-brain barrier and arterial phenotypes.PLoS One. 2014;9:e84179-e84179
73. Al Ahmad A,Taboada CB,Gassmann M,Ogunshola OO.Astrocytes and pericytes differentially modulate blood-brain barrier characteristics during development and hypoxic insult.J Cereb Blood Flow Metab. 2011;31:693-705
74. Hatherell K,Couraud PO,Romero IA,Weksler B,Pilkington GJ.Development of a three-dimensional, all-human in vitro model of the blood-brain barrier using mono-, co-, and tri-cultivation Transwell models.J Neurosci Methods. 2011;199:223-9
75. Lippmann ES,Azarin SM,Kay JE,Nessler RA,Wilson HK,Al-Ahmad A,Palecek SP,Shusta EV.Derivation of blood-brain barrier endothelial cells from human pluripotent stem cells.Nat Biotechnol. 2012;30:783-91
76. Cucullo L,Hossain M,Tierney W,Janigro D.A new dynamic in vitro modular capillaries-venules modular system: cerebrovascular physiology in a box.BMC Neurosci. 2013;14:18-18
77. Kim S,Lee H,Chung M,Jeon NL.Engineering of functional, perfusable 3D microvascular networks on a chip.Lab Chip. 2013;13:1489-500
78. Arisaka T,Mitsumata M,Kawasumi M,Tohjima T,Hirose S,Yoshida Y.Effects of shear stress on glycosaminoglycan synthesis in vascular endothelial cells.Ann New York Acad Sci. 1995;748:543-54
79. Prabhakarpandian B,Shen MC,Nichols JB,Mills IR,Sidoryk-Wegrzynowicz M,Aschner M,Pant K.SyM-BBB: a microfluidic blood brain barrier model.Lab Chip. 2013;13:1093-101
80. Griep LM,Wolbers F,De Wagenaar B,Ter Braak PM,Weksler BB,Romero IA,Couraud PO,Vermes I,Van der Meer AD,Van den Berg A.BBB on chip: microfluidic platform to mechanically and biochemically modulate blood-brain barrier function.Biomed Microdevices. 2013;15:145-50
81. Yeon JH,Na D,Choi K,Ryu SW,Choi C,Park JK.Reliable permeability assay system in a microfluidic device mimicking cerebral vasculatures.Biomed Microdevices. 2012;14:1141-8
82. Booth R,Kim H.Characterization of a microfluidic in vitro model of the blood-brain barrier (muBBB).Lab Chip. 2012;12:1784-92
83. Takahashi K,Yamanaka S.Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors.Cell. 2006;126:663-76
84. Takahashi K,Tanabe K,Ohnuki M,Narita M,Ichisaka T,Tomoda K,Yamanaka S.Induction of pluripotent stem cells from adult human fibroblasts by defined factors.Cell. 2007;131:861-72
85. Yu J,Vodyanik MA,Smuga-Otto K,Antosiewicz-Bourget J,Frane JL,Tian S,Nie J,Jonsdottir GA,Ruotti V,Stewart R,Slukvin II,Thomson JA.Induced pluripotent stem cell lines derived from human somatic cells.Science. 2007;318:1917-20
86. Maherali N,Sridharan R,Xie W,Utikal J,Eminli S,Arnold K,Stadtfeld M,Yachechko R,Tchieu J,Jaenisch R,Plath K,Hochedlinger K.Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution.Cell Stem Cell. 2007;1:55-70
87. Hussein SM,Nagy AA.Progress made in the reprogramming field: new factors, new strategies and a new outlook.Curr Opin Genet Dev. 2012;22:435-43
88. Barker RA,De Beaufort I.Scientific and ethical issues related to stem cell research and interventions in neurodegenerative disorders of the brain.Prog Neurobiol. 2013;110:63-73
89. Bilic J,Izpisua Belmonte JC.Concise review: induced pluripotent stem cells versus embryonic stem cells: close enough or yet too far apart?.Stem Cells. 2012;30:33-41
90. Lister R,Pelizzola M,Kida YS,Hawkins RD,Nery JR,Hon G,Antosiewicz-Bourget J,O’Malley R,Castanon R,Klugman S,Downes M,Yu R,Stewart R,Ren B,Thomson JA,Evans RM,Ecker JR.Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells.Nature. 2011;471:68-73
91. Yan Y,Yang D,Zarnowska ED,Du Z,Werbel B,Valliere C,Pearce RA,Thomson JA,Zhang SC.Directed differentiation of dopaminergic neuronal subtypes from human embryonic stem cells.Stem Cells. 2005;23:781-90
92. Vazin T,Becker KG,Chen J,Spivak CE,Lupica CR,Zhang Y,Worden L,Freed WJ.A novel combination of factors, termed SPIE, which promotes dopaminergic neuron differentiation from human embryonic stem cells.PLoS One. 2009;4:e6606-e6606
93. Zhang XQ,Zhang SC.Differentiation of neural precursors and dopaminergic neurons from human embryonic stem cells.Methods Mol Biol. 2010;584:355-66
94. Juopperi TA,Kim WR,Chiang CH,Yu H,Margolis RL,Ross CA,Ming GL,Song H.Astrocytes generated from patient induced pluripotent stem cells recapitulate features of Huntington’s disease patient cells.Mol Brain. 2012;5:17-17
95. Ogawa S,Tokumoto Y,Miyake J,Nagamune T.Induction of oligodendrocyte differentiation from adult human fibroblast-derived induced pluripotent stem cells.In Vitro Cell Dev Biol Anim. 2011;47:464-9
96. Wang S,Bates J,Li X,Schanz S,Chandler-Militello D,Levine C,Maherali N,Studer L,Hochedlinger K,Windrem M,Goldman SA.Human iPSC-derived oligodendrocyte progenitor cells can myelinate and rescue a mouse model of congenital hypomyelination.Cell Stem Cell. 2013;12:252-64
97. Gaspard N,Bouschet T,Hourez R,Dimidschstein J,Naeije G,Van den Ameele J,Espuny-Camacho I,Herpoel A,Passante L,Schiffmann SN,Gaillard A,Vanderhaeghen P.An intrinsic mechanism of corticogenesis from embryonic stem cells.Nature. 2008;455:351-7
98. Eiraku M,Watanabe K,Matsuo-Takasaki M,Kawada M,Yonemura S,Matsumura M,Wataya T,Nishiyama A,Muguruma K,Sasai Y.Self-organized formation of polarized cortical tissues from ESCs and its active manipulation by extrinsic signals.Cell Stem Cell. 2008;3:519-32
99. Lancaster MA,Renner M,Martin CA,Wenzel D,Bicknell LS,Hurles ME,Homfray T,Penninger JM,Jackson AP,Knoblich JA.Cerebral organoids model human brain development and microcephaly.Nature. 2013;501:373-9
100. Mariani J,Simonini MV,Palejev D,Tomasini L,Coppola G,Szekely AM,Horvath TL,Vaccarino FM.Modeling human cortical development in vitro using induced pluripotent stem cells.Proc Natl Acad Sci USA. 2012;109:12770-5
101. Xia X,Zhang SC.Differentiation of neuroepithelia from human embryonic stem cells.Methods Mol Biol. 2009;549:51-8
102. Bershteyn M,Kriegstein AR.Cerebral organoids in a dish: progress and prospects.Cell. 2013;155:19-20
103. Hu BY,Zhang SC.Differentiation of spinal motor neurons from pluripotent human stem cells.Nat Protoc. 2009;4:1295-304
104. Tilgner K,Neganova I,Singhapol C,Saretzki G,Al-Aama JY,Evans J,Gorbunova V,Gennery A,Przyborski S,Stojkovic M,Armstrong L,Jeggo P,Lako M.Brief report: a human induced pluripotent stem cell model of cernunnos deficiency reveals an important role for XLF in the survival of the primitive hematopoietic progenitors.Stem Cells. 2013;31:2015-23
105. Liu Y,Lopez-Santiago LF,Yuan Y,Jones JM,Zhang H,O’Malley HA,Patino GA,O’Brien JE,Rusconi R,Gupta A,Thompson RC,Natowicz MR,Meisler MH,Isom LL,Parent JM.Dravet syndrome patient-derived neurons suggest a novel epilepsy mechanism.Ann Neurol. 2013;74:128-39
106. Jiao J,Yang Y,Shi Y,Chen J,Gao R,Fan Y,Yao H,Liao W,Sun X,Gao S.Modeling Dravet syndrome using induced pluripotent stem cells (iPSCs) and directly converted neurons.Hum Mol Genet. 2013;1:4241-52
107. Sheridan SD,Theriault KM,Reis SA,Zhou F,Madison JM,Daheron L,Loring JF,Haggarty SJ.Epigenetic characterization of the FMR1 gene and aberrant neurodevelopment in human induced pluripotent stem cell models of fragile X syndrome.PLoS One. 2011;6:e26203-e26203
108. Ananiev G,Williams EC,Li H,Chang Q.Isogenic pairs of wild type and mutant induced pluripotent stem cell (iPSC) lines from Rett syndrome patients as in vitro disease model.PLoS One. 2011;6:e25255-e25255
109. Dajani R,Koo SE,Sullivan GJ,Park IH.Investigation of Rett syndrome using pluripotent stem cells.J Cell Biochem. 2013;114:2446-53
110. Brennand KJ,Simone A,Jou J,Gelboin-Burkhart C,Tran N,Sangar S,Li Y,Mu Y,Chen G,Yu D,McCarthy S,Sebat J,Gage FH.Modelling schizophrenia using human induced pluripotent stem cells.Nature. 2011;473:221-5
111. Chang T,Zheng W,Tsark W,Bates S,Huang H,Lin RJ,Yee JK.Brief report: phenotypic rescue of induced pluripotent stem cell-derived motoneurons of a spinal muscular atrophy patient.Stem Cells. 2011;29:2090-3
112. Krey JF,Pasca SP,Shcheglovitov A,Yazawa M,Schwemberger R,Rasmusson R,Dolmetsch RE.Timothy syndrome is associated with activity-dependent dendritic retraction in rodent and human neurons.Nat Neurosci. 2013;16:201-9
113. Pasca SP,Portmann T,Voineagu I,Yazawa M,Shcheglovitov A,Pasca AM,Cord B,Palmer TD,Chikahisa S,Nishino S,Bernstein JA,Hallmayer J,Geschwind DH,Dolmetsch RE.Using iPSC-derived neurons to uncover cellular phenotypes associated with Timothy syndrome.Nat Med. 2011;17:1657-62
114. Yi F,Qu J,Li M,Suzuki K,Kim NY,Liu GH,Belmonte JC.Establishment of hepatic and neural differentiation platforms of Wilson’s disease specific induced pluripotent stem cells.Protein Cell. 2012;3:855-63
115. Consortium THi.Induced pluripotent stem cells from patients with Huntington’s disease show CAG-repeat-expansion-associated phenotypes.Cell Stem Cell. 2012;11:264-78
116. Bal-Price AK,Hogberg HT,Buzanska L,Lenas P,Van Vliet E,Hartung T.In vitro developmental neurotoxicity (DNT) testing: relevant models and endpoints.Neurotoxicology. 2010;31:545-54
117. De la Monte SM,Tong M,Carlson RI,Carter JJ,Longato L,Silbermann E,Wands JR.Ethanol inhibition of aspartyl-asparaginyl-beta-hydroxylase in fetal alcohol spectrum disorder: potential link to the impairments in central nervous system neuronal migration.Alcohol. 2009;43:225-40
118. Moors M,Rockel TD,Abel J,Cline JE,Gassmann K,Schreiber T,Schuwald J,Weinmann N,Fritsche E.Human neurospheres as three-dimensional cellular systems for developmental neurotoxicity testing.Environ Health Perspect. 2009;117:1131-8
119. Stern M,Gierse A,Tan S,Bicker G.Human Ntera2 cells as a predictive in vitro test system for developmental neurotoxicity.Arch Toxicol. 2014;88:127-36
120. Krug AK,Balmer NV,Matt F,Schonenberger F,Merhof D,Leist M.Evaluation of a human neurite growth assay as specific screen for developmental neurotoxicants.Arch Toxicol. 2013;87:2215-31
121. Brewer GJ,Boehler MD,Pearson RA,DeMaris AA,Ide AN,Wheeler BC.Neuron network activity scales exponentially with synapse density.J Neural Eng. 2009;6:014001-014001
122. Harrill JA,Robinette BL,Mundy WR.Use of high content image analysis to detect chemical-induced changes in synaptogenesis in vitro.Toxicol In Vitro. 2011;25:368-87
123. Li H,Foss SM,Dobryy YL,Park CK,Hires SA,Shaner NC,Tsien RY,Osborne LC,Voglmaier SM.Concurrent imaging of synaptic vesicle recycling and calcium dynamics.Front Mol Neurosci. 2011;4:34-34
124. Nakai J,Ohkura M,Imoto K.A high signal-to-noise Ca(2+) probe composed of a single green fluorescent protein.Nat Biotechnol. 2001;19:137-41
125. Gramowski A,Jugelt K,Stuwe S,Schulze R,McGregor GP,Wartenberg-Demand A,Loock J,Schroder O,Weiss DG.Functional screening of traditional antidepressants with primary cortical neuronal networks grown on multielectrode neurochips.Eur J Neurosci. 2006;24:455-65
126. Gramowski A,Jugelt K,Weiss DG,Gross GW.Substance identification by quantitative characterization of oscillatory activity in murine spinal cord networks on microelectrode arrays.Eur J Neurosci. 2004;19:2815-25
127. Johnstone AF,Gross GW,Weiss DG,Schroeder OH,Gramowski A,Shafer TJ.Microelectrode arrays: a physiologically based neurotoxicity testing platform for the 21st century.Neurotoxicology. 2010;31:331-50
128. Makinen M,Joki T,Yla-Outinen L,Skottman H,Narkilahti S,Aanismaa R.Fluorescent probes as a tool for cell population tracking in spontaneously active neural networks derived from human pluripotent stem cells.J Neurosci Methods. 2013;215:88-96
129. Felitsyn N,McLeod C,Shroads AL,Stacpoole PW,Notterpek L.The heme precursor delta-aminolevulinate blocks peripheral myelin formation.J Neurochem. 2008;106:2068-79
130. Bal-Price A,Moneer Z,Brown GC.Nitric oxide induces rapid, calcium-dependent release of vesicular glutamate and ATP from cultured rat astrocytes.Glia. 2002;40:312-23
131. Ross IA,Johnson W,Sapienza PP,Kim CS.Effects of the seafood toxin domoic acid on glutamate uptake by rat astrocytes.Food Chem Toxicol. 2000;38:1005-11
132. Radio NM,Freudenrich TM,Robinette BL,Crofton KM,Mundy WR.Comparison of PC12 and cerebellar granule cell cultures for evaluating neurite outgrowth using high content analysis.Neurotoxicol Teratol. 2010;32:25-35
133. Meli L,Jordan ET,Clark DS,Linhardt RJ,Dordick JS.Influence of a three-dimensional, microarray environment on human cell culture in drug screening systems.Biomaterials. 2012;33:9087-96
134. Krausz E,De Hoogt R,Gustin E,Cornelissen F,Grand-Perret T,Janssen L,Vloemans N,Wuyts D,Frans S,Axel A,Peeters PJ,Hall B,Cik M.Translation of a tumor microenvironment mimicking 3D tumor growth co-culture assay platform to high-content screening.J Biomol Screen. 2013;18:54-66
135. Lee LH,Peerani R,Ungrin M,Joshi C,Kumacheva E,Zandstra P.Micropatterning of human embryonic stem cells dissects the mesoderm and endoderm lineages.Stem Cell Res. 2009;2:155-62
136. Lampe KJ,Mooney RG,Bjugstad KB,Mahoney MJ.Effect of macromer weight percent on neural cell growth in 2D and 3D nondegradable PEG hydrogel culture.J Biomed Materials Res Part A. 2010;94:1162-71
137. Hartung T.Lessons learned from alternative methods and their validation for a new toxicology in the 21st century.J Toxicol Environ Health B Crit Rev. 2010;13:277-90
138. OECD. No. 34: Guidance document on the validation and international acceptance of new or updated test methods for hazard assessment. OECD Publishing 2005, http://iccvam.niehs.nih.gov/SuppDocs/FedDocs/OECD/OECD-GD34.pdf (accessed 15 October 2013).
139. Hartung T,Bremer S,Casati S,Coecke S,Corvi R,Fortaner S,Gribaldo L,Halder M,Hoffmann S,Roi AJ,Prieto P,Sabbioni E,Scott L,Worth A,Zuang V.A modular approach to the ECVAM principles on test validity.Altern Lab Anim: ATLA. 2004;32:467-72
140. Hartung T.Food for thought…on validation.Altex. 2007;24:67-80
141. Leist M,Hasiwa N,Daneshian M,Hartung T.Validation and quality control of replacement alternatives – current status and future challenges.Toxicol Res. 2012;1:8-22
142. Hartung T.Evidence-based toxicology – the toolbox of validation for the 21st century?.Altex. 2010;27:253-63
143. Hoffmann S,Hartung T.Toward an evidence-based toxicology.Hum Exp Toxicol. 2006;25:497-513
144. EBTC, http://ebtox.com/ (accessed 15 OCtober 2013).
145. Zurlo J,Hartung T.Evidence-based toxicology collaboration kick-off meeting.Altex. 2011;28:152-152
146. Hartung T,Hoffmann S,Stephens M.Mechanistic validation.Altex. 2013;30:119-30